Dr. Peter Paul Ventre, MD

Dr. Ventre practices at Children's National Hospital in Washington, District of Columbia, part of Children's National Hospital.

Dr. Ventre's NPI, 1659569952, was assigned on October 11, 2007. Dr. Ventre holds Florida license ME103007.

Dr. Ventre's primary practice is Children's National Hospital, at 111 Michigan Ave, NW, Washington, DC 20010 in The District County. The practice phone is (202) 476-5000.

Dr. Ventre's primary practice is Children's National Hospital in Washington, District of Columbia, part of Children's National Hospital. The medical group on file is Ventre Medical Associates. Dmand AI also links Dr. Ventre to 1 more dialysis center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ventre practices, 3 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Ventre's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Ventre is licensed in Florida.

CMS data shows 20 Medicare services from Dr. Ventre across 1 procedure code in 2024, all of them office visits, for 26 Medicare patients. Medicare paid $961 for them. Every service was in an office.

CMS counts 26 Medicare patients who saw Dr. Ventre in 2024. The largest group is 65 to 74, with 13 patients. 75% of them have anxiety, and 75% have depression. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ventre's median patient age at 49, with 67% women.

In 2024, Dr. Ventre wrote 132 Medicare Part D claims for 33 patients. CMS names the drug for 60 of them, across 1 drug with 11 or more claims each, at $85,075 in total drug cost. In 2023, CMS named 150 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 52 out of 100 for Dr. Ventre for performance year 2024, reported as part of a group. Dr. Ventre accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Ventre to 2 clinical trials. Conditions studied include Depressive Disorder, Treatment-Resistant, Fibromyalgia and Depressive Disorder. Open Payments lists research payments to Dr. Ventre that name 1 trial.

CMS Open Payments shows 106 general payments to Dr. Ventre from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Eli Lilly and Company paid the most, $15,648. It also lists 10 research payments totaling $3,146 from 2016 to 2017, naming 1 clinical trial.